Dermira, Inc. (NASDAQ:DERM) insider Eugene A. Bauer sold 7,500 shares of the stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total value of $225,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.04). The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.00 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%.
A number of analysts have weighed in on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $45.00 price objective on shares of Dermira in a research report on Tuesday, September 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price objective on shares of Dermira in a research report on Sunday, September 17th. Mizuho reaffirmed a “buy” rating and set a $43.00 price objective (up from $40.00) on shares of Dermira in a research report on Thursday, September 7th. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, BidaskClub raised Dermira from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 16th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $44.40.
Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in shares of Dermira during the first quarter worth approximately $1,023,000. Vanguard Group Inc. lifted its position in Dermira by 20.7% in the first quarter. Vanguard Group Inc. now owns 1,272,700 shares of the biopharmaceutical company’s stock worth $43,412,000 after purchasing an additional 217,943 shares during the period. Rhumbline Advisers lifted its position in Dermira by 57.1% in the second quarter. Rhumbline Advisers now owns 43,781 shares of the biopharmaceutical company’s stock worth $1,276,000 after purchasing an additional 15,905 shares during the period. Platinum Investment Management Ltd. lifted its position in Dermira by 28.8% in the second quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock worth $1,681,000 after purchasing an additional 12,900 shares during the period. Finally, Nicholas Investment Partners LP lifted its position in Dermira by 19.3% in the second quarter. Nicholas Investment Partners LP now owns 127,004 shares of the biopharmaceutical company’s stock worth $3,704,000 after purchasing an additional 20,587 shares during the period. Institutional investors and hedge funds own 97.56% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.